Time Commitment: Screening Phase (may be up to 6o days) and Treatment Phase (4 visits over a 12 month period)Īnticipated Benefits: You may or may not benefit from participating in this study. Location: UCI Campus (1100 Gottschalk Medical Plaza, Irvine ICTS at Hewitt Hall, Irvine and Newport Diagnostic Center, Newport Beach) UCLA (Center for Neurotherapeutics UCLA Medical Center 300 Medical Plaza, Westwood Blvd Los Angeles) Purpose of Study: To evaluate whether nicotinamide, also known as vitamin B3 or niacinamide, can reduce phosphorylation or “over-processing” of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer’s disease (AD) dementia.Įligibility: Men and women, aged 50 years and above and diagnosed with Mild Cognitive Impairment or mild dementia due to Alzheimer’s disease.
#Parallels for mac uc irvine trial
Study Title: A Phase 2, Proof-of-Concept, Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in MCI due to AD and Mild AD Dementia
Lead researcher: Joshua Grill, PhD and Steven Tam, MD Researchers at UCI and UCLA are conducting a new study to test whether high doses of nicotinamide (a component of vitamin B3) can halt or reverse neurofibrillary tangles in Alzheimer’s disease.
0 kommentar(er)
